Abstract
The goal of this double-blind, randomized, placebo-controlled trial was to evaluate the effects of a cross-linked polyelectrolyte (CLP) on serum potassium and measures of congestion in patients with heart failure (HF) and chronic kidney disease (CKD). The pre-specified primary endpoint was change in serum K+ over time, with an associated goal of facilitating the initiation of aldosterone blockers in patients at risk for hyperkalemia. Since CLP also removes fluid through the GI tract, we also hypothesized that this intervention would ameliorate congestion as assessed by serial weights and its associated symptoms, as assessed by NYHA class, quality of life (assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ), and 6 minute walk test (6MWT) after 8 weeks of CLP treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
